Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs SYSCO Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $355.41 (market cap $9.43B), while SYSCO Corporation trades at $84.42 (market cap $40.32B). The key difference: SYSCO Corporation is far larger — about 4.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and SYSCO Corporation pays a 2.61% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SYY | |
|---|---|---|
Market Cap | $9.43B | $40.32B |
Sector | Health | Consumer Staples |
52-Week High | $356.25 | $91.16 |
52-Week Low | $241.71 | $69.30 |
Enterprise Value | $9.18B | $53.50B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
SYY trades at $83.87, down 0.5% for the day, with a neutral technical signal and bullish moving averages. The company reported Q4 2026 EPS of $1.53, beating estimates, and revenue of $81.37B in 2025, with steady growth. Analyst consensus is a Buy with a $88.25 price target, and recent news highlights strong quarterly results and efficiency initiatives.
Outlook is positive due to earnings beats and growth initiatives, but risks include margin pressure and debt levels. The stock offers value with a P/E of 23.02 and P/S of 0.48, supported by institutional optimism, though macroeconomic uncertainty remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
